ARTICLE | Product Development
Anokion puts liver to the test
Anokion’s preclinical data showcase induction of immune tolerance via liver-targeted autoantigens
September 19, 2019 8:49 PM UTC
Data presented Sept. 13 at a major multiple sclerosis meeting showcased the ability of Anokion’s liver targeting technology to induce immune tolerance.
Armed with a fresh $40 million series B round, Anokion S.A. is developing a platform to treat autoimmune disease by inducing tolerance via liver-targeted autoantigens (see “Anokion’s autoimmunity platform evolution”)...